Severe neutropenia among healthy volunteers given rifabutin in clinical trials

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 6, 2003, Pages 592-593

  Flexner, Charles ^a   Barditch Crovo, Patricia A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN;

BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEVER; HUMAN; LETTER; LIVER TOXICITY; NEUTROPENIA; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 0347386410     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.08.005     Document Type: Letter

References (9)

1. Apseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin Pharmacol Ther 2003;74:591-2.
2. Apseloff G, Foulds G, LaBoy-Goral L, Kraut E, Vincent J. Severe neutropenia caused by recommended prophylactic doses of rifabutin [letter]. Lancet 1996;348:685.
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
4. Caperna J, Barber RE, Toerner JG, Mathews WC. Estimation of the effect of neutropenia on rates of clinical bacteraemia in HIV-infected patients. Epidemiol Infect 1998;120:71-80.
5. Barditch-Crovo PA, Trapnell CB, Ette E, Zacur H, Coresh J, Rocco LE, et al. Comparison of the effects of rifampin and rifabutin on the pharmacokinetics and pharmacologic effects of a combined oral contraceptive. Clin Pharmacol Ther 1999;65:428-38.
6. Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, et al. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003;73:159-69.
7. Mycobutin (rifabutin) [product monograph]. Peapack (NJ): Pharmacia and Upjohn; 2003.
8. Griffith DE, Brown BA, Girard WM, Wallace RJ. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995:21:594-8.
9. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.